Avidity Biosciences (RNA) Liabilities and Shareholders Equity: 2019-2024
Historic Liabilities and Shareholders Equity for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $1.6 billion.
- Avidity Biosciences' Liabilities and Shareholders Equity rose 30.07% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 billion, marking a year-over-year increase of 42.86%. This contributed to the annual value of $1.6 billion for FY2024, which is 148.81% up from last year.
- According to the latest figures from FY2024, Avidity Biosciences' Liabilities and Shareholders Equity is $1.6 billion, which was up 148.81% from $628.6 million recorded in FY2023.
- Avidity Biosciences' 5-year Liabilities and Shareholders Equity high stood at $1.6 billion for FY2024, and its period low was $333.9 million during FY2020.
- Over the past 3 years, Avidity Biosciences' median Liabilities and Shareholders Equity value was $638.8 million (recorded in 2022), while the average stood at $943.8 million.
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 244.56% in 2020, then decreased by 1.60% in 2023.
- Over the past 5 years, Avidity Biosciences' Liabilities and Shareholders Equity (Yearly) stood at $333.9 million in 2020, then climbed by 28.06% to $427.6 million in 2021, then spiked by 49.40% to $638.8 million in 2022, then decreased by 1.60% to $628.6 million in 2023, then skyrocketed by 148.81% to $1.6 billion in 2024.